Hypertension and incident cardiovascular events following ibrutinib initiation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hypertension and incident cardiovascular events following ibrutinib initiation
Authors
Keywords
-
Journal
BLOOD
Volume 134, Issue 22, Pages 1919-1928
Publisher
American Society of Hematology
Online
2019-10-04
DOI
10.1182/blood.2019000840
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
- (2019) Daniel Caldeira et al. PLoS One
- Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
- (2018) Inhye E. Ahn et al. BLOOD
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- Safety Analysis of 4 Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
- (2018) Susan O'Brien et al. Clinical Lymphoma Myeloma & Leukemia
- Hypertension in malignancy–an underappreciated problem
- (2018) Jolanta Małyszko et al. Oncotarget
- Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies
- (2018) Avirup Guha et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
- (2017) Lingyan Ping et al. Oncotarget
- The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
- (2016) Darryl P. Leong et al. BLOOD
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation
- (2016) Na Wu et al. Scientific Reports
- Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- A Randomized Trial of Intensive versus Standard Blood-Pressure Control
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells
- (2015) Gayathri Natarajan et al. OncoImmunology
- Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study
- (2015) Amirrtha Srikanthan et al. PLoS One
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells
- (2014) Wen Gao et al. JNCI-Journal of the National Cancer Institute
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Risk Score for Predicting Near-Term Incidence of Hypertension: The Framingham Heart Study
- (2013) Nisha I. Parikh et al. ANNALS OF INTERNAL MEDICINE
- 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
- (2013) Paul A. James et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
- (2010) Rebecca L Stone et al. LANCET ONCOLOGY
- Reduced Phosphoinositide 3-Kinase (p110α) Activation Increases the Susceptibility to Atrial Fibrillation
- (2009) Lynette Pretorius et al. AMERICAN JOURNAL OF PATHOLOGY
- Interleukin 17 Promotes Angiotensin II–Induced Hypertension and Vascular Dysfunction
- (2009) Meena S. Madhur et al. HYPERTENSION
- Association Between Blood Pressure Variability and Inflammatory Marker in Hypertensive Patients
- (2008) Kwang-Il Kim et al. CIRCULATION JOURNAL
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now